Last reviewed · How we verify
maintenance therapy
Maintenance therapy involves the use of medications to prevent disease recurrence or progression.
Maintenance therapy involves the use of medications to prevent disease recurrence or progression. Used for Maintenance therapy for various cancers.
At a glance
| Generic name | maintenance therapy |
|---|---|
| Also known as | 6-mercaptopurine,Methotrexate |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Maintenance therapy typically involves the long-term administration of medications to manage chronic conditions, such as cancer or autoimmune diseases. This approach aims to prevent disease recurrence or progression, and may involve the use of combination therapies or targeted treatments.
Approved indications
- Maintenance therapy for various cancers
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures (PHASE4)
- Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain (NA)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- maintenance therapy CI brief — competitive landscape report
- maintenance therapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI